IL4 and Alzheimer disease: Most recently, crisaborole, a topical phosphodiesterase-4 inhibitor, and dupilumab, an inhibitor of interleukin (IL)-4/13, were FDA-approved, with studies showing an excellent safety profile for chronic treatment in AD [11].